27.3 C
Vientiane
Saturday, June 28, 2025
spot_img
Home Blog Page 46

TXOne Networks Introduces Breakthrough Capability for Intelligent Vulnerability Mitigation in New Release of TXOne SageOne

TXOne Networks’ OT Cybersecurity Governance Platform uniquely provides meaningful guidance on which CPS vulnerabilities legitimately require priority attention to safeguard operations

TAIPEI, June 4, 2025 /PRNewswire/ — TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, today announced an expanded new version of its SageOne OT Cybersecurity Governance Platform. Already relied upon by many industrial leaders across sectors with exacting cybersecurity requirements, TXOne SageOne has been enhanced to deliver a novel capability for intelligent vulnerability mitigation.

TXOne SageOne provides a comprehensive, detailed and easy-to-understand visualization of the precise security posture of operations at any given moment
TXOne SageOne provides a comprehensive, detailed and easy-to-understand visualization of the precise security posture of operations at any given moment

One of the most common challenges faced by (operational technology) OT cybersecurity practitioners is how to patch effectively under time constraints—making risk-based prioritization essential. TXOne SageOne uniquely integrates external intelligence on emerging threats, the specific operational context of each manufacturer and industry-standard vulnerability scoring to provide meaningful, tailored guidance to the organization’s security team. The TXOne Networks solution implements a rigorous, three-phase approach to risk-based vulnerability management:

  • Assess—TXOne SageOne pulls deep, OS-level vulnerability and configuration data—augmented by real-time threat intelligence—to build an accurate, context-rich view of every CPS asset’s true risk exposure.
  • Prioritize—Asset criticality, observed attack patterns and existing defenses are fused into TXOne Networks’ proprietary Vulnerability Situational Awareness Rating (VSAR) risk score to distill thousands of potential flaws to the few that truly demand attention.
  • Remediate—TXOne SageOne automatically interprets each asset’s context (device type, operational status and business impact) and prescribes the optimal mitigation path (full patching, virtual patching or just-In-time guided micro-segmentation) without disrupting production.

CPS consist of mission-critical assets and sophisticated computation and shutting down a production line to implement a patch on such a system or to undertake other protective measures in the OT network generally is not an option. Conventional cybersecurity management platforms rely on vulnerability scoring that is predicated on concepts and protocols borrowed from information technology (IT). That information is useful in OT cybersecurity—but impractical if relied upon alone. Conventional systems often indicate thousands of high-priority vulnerabilities across a large-scale manufacturing environment. A security team tasked with securing OT often is no more than 10 people, so the practical reality is the majority of alerts generated by today’s conventional systems go unaddressed.

TXOne SageOne, however, narrows guidance to a manageable number of legitimately critical vulnerabilities that demand immediate action across a given manufacturer’s OT threat landscape. Armed with a holistic, dependable overview of the truly urgent threats to its corporate environment, the security team is positioned to immediately take concrete, meaningful steps to protect people, OT assets and processes.

“TXOne SageOne represents a breakthrough in OT security governance, having been conceived and purpose-built from the ground up to address the unique cybersecurity needs of OT networks and systems—not IT,” said Dr. Terence Liu, CEO of TXOne Networks. “The latest release introduces intelligent vulnerability mitigation capabilities that underscore this differentiation, empowering security teams with tools tailored to the specific nature of OT environments and delivering actionable insights that lead to achievable, impactful outcomes.

All of TXOne Networks’ industry-leading point products for CPS security are centrally controlled via the SageOne platform—Stellar for endpoint protection, Element for security inspection and Edge for network defense. As the central hub for all TXOne Networks security offerings, SageOne brings Element, Stellar, and Edge into seamless collaboration to deliver unified visibility, centralized control and optimized vulnerability management. TXOne SageOne provides a comprehensive, detailed and easy-to-understand visualization of the precise security posture of operations at any given moment.

For more information on TXOne SageOne, please visit https://www.txone.com/products/cps-protection-platform/txone-sageone/.

Follow TXOne Networks on Blog, Twitter, and LinkedIn.

About TXOne Networks 

TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com

Octa broker’s survey: Malaysian traders’ security stance


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 4 June 2025 – Octa, a global regulated broker since 2011, conducted a survey to learn more about Malaysian traders’ security habits and behaviours, both in everyday life and in trading. Below are some insightful takeaways on how traders approach one of the most crucial aspects of their craft.

Octa Broker

There is an old saying, ‘How you do anything is how you do everything.’ Whatever its initial source, this piece of wisdom is remarkably applicable to trading. With that idea in mind, Octa, a globally trusted and regulated broker, surveyed Malaysian traders about their stance towards security in life and trading. The survey showed some interesting correlations.

Suspended judgement
According to Octa’s survey, 83% of Malaysian traders tend not to trust new acquaintances too easily. They prefer getting to know a new person for several months before entirely relying on them. The remaining 17% approach this aspect of their life in a much more nonchalant manner, saying they only need several hours or less to start trusting a new person.

This reserved attitude towards new people displayed by Malaysian traders matches their stance towards choosing a financial broker. 92% conduct thorough research and scrutinise online reviews before putting their trust in a broker, while only 8% make this decision without proper groundwork.

This symmetry in attitudes speaks volumes about people’s mentality, but the key takeaway is this: in life, as in trading, Malaysian traders tend to display a cold-headed approach. They opt for transparency and require as much information as reasonably possible before making a crucial decision, whether in their life or finances.

As a broker with a long and successful track record, Octa fully supports this stance and advises traders to test its advantageous conditions and fast withdrawals first-hand instead of mindlessly trusting advertisements. This way, traders can ensure Octa discloses all its fees and conditions without any hidden tricks—just fair and transparent trading.

A disciplined approach to finances
The survey showed that 84% of traders pay their utility bills in advance, while only 16% do it at the last minute, despite having no money issues. Surprising though it may seem, this lifestyle choice does not entirely match the participants’ stance towards risk management in trading. About 30% of respondents use stop-loss and take-profit orders only when attempting an especially hazardous trade. In most cases, they rely on their intuition and experience.

Octa Broker

It is worth noting that those who always pay their bills on time are much more likely to use risk management tools in their trading sessions. They carefully set stop-loss and take-profit orders, keep track of their equity level, and calculate potential financial outcomes before taking a position. On the other hand, 48% of those who couldn’t be bothered to pay their bills in advance tend to skip the risk management tools, trusting their gut feeling.

To sum up, traders often transfer their financial stance in life to their trading routine. In wealth management, taking a proactive stance often pays off, as you mitigate the risks and avoid unnecessary complications.

Another crucial step to mitigate risks is to choose a broker with fast and efficient withdrawals. For example, Octa taps into its extensive global expertise to ensure a secure and reliable withdrawal procedure whose efficiency is supported by thousands of user reviews.

Aspirations vs. reality
When asked how they envisage their dream workplace, 89% of survey participants chose a meticulously clean, secure, and well-organised environment that emits stability vibes. Only 11% opted for a beautiful and unique, yet chaotic and unpredictable environment. This shows a very strong tendency towards an organised, disciplined approach.

On the other hand, according to Octa’s research, 68% of Malaysian traders don’t plan their trading sessions and access their trading app whenever they feel like it. This statistic reveals a distinct tendency to approach trading with a degree of nonchalance that can harm financial outcomes.

The conclusion is simple: leaning towards discipline and efficient planning is one thing, but putting this principle into practice and strategising each session in advance is much more challenging.
___

Disclaimer: This content is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to engage in any investment activity. It does not take into account your investment objectives, financial situation, or individual needs. Any action you take based on this content is at your sole discretion and risk. Octa and its affiliates accept no liability for any losses or consequences resulting from reliance on this material.
Trading involves risks and may not be suitable for all investors. Use your expertise wisely and evaluate all associated risks before making an investment decision. Past performance is not a reliable indicator of future results.
Availability of products and services may vary by jurisdiction. Please ensure compliance with your local laws before accessing them.

Hashtag: #Octa

The issuer is solely responsible for the content of this announcement.

Octa

is an international CFD broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services used by clients from 180 countries who have opened more than 52 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools.

The company is involved in a comprehensive network of charitable and humanitarian initiatives, including improving educational infrastructure and funding short-notice relief projects to support local communities.

In Southeast Asia, Octa received the ‘Best Trading Platform Malaysia 2024’ and the ‘Most Reliable Broker Asia 2023’ awards from Brands and Business Magazine and International Global Forex Awards, respectively.

“Care burnout” is costing Australians their health, careers, and up to $18K a year

9 in 10 Australians in the Sandwich Generation are experiencing signs of burnout, spending on average nearly 30 hours a week caring for older and younger generations

SYDNEY, June 4, 2025 /PRNewswire/ — Australia’s “sandwich generation,” juggling care for older and younger relatives, faces devastating impacts on wellbeing, reveals the Sandwich Generation Report 2025 by Australian Seniors. A staggering nine in 10 (90%) experience caregiving burnout, dedicating nearly 30 hours weekly—1,500 hours a year—to care, severely limiting personal time.

“This report brings a hidden crisis to light; the burnout among sandwich generation carers is unsustainable and demands immediate attention,” said Annabel Reid, CEO of Carers Australia. These carers dedicate nearly 30 hours weekly—1,500 hours a year—to care, severely limiting personal time. This impacts social connections (48% affected) and leads to self-sacrifice, with 38% (44% of women) regularly prioritising others’ needs.

Financial and health tolls mount

The rising cost of living intensifies financial strain. Nearly half (49%) find supporting both generations challenging, contributing up to $18,000 annually for ageing parents, while 83% also support younger relatives, often for essential daily living costs like groceries and bills. Concerningly, only 23% access financial support, often due to lack of awareness (39%).

The health toll is severe, with many suffering in silence: 70% of carers over 50 report physical symptoms like chronic fatigue and pain. Emotional exhaustion (47%) and sleep disturbances (46%) are common. Nearly half (46%, 55% of women) never take health-focused breaks, with 65% fearing long-term wellbeing impacts.

Workplace challenges and gender disparity

Workplace pressures are acute: 52% report increased stress, and 53% receive only partial employer support. This forces difficult choices, with 53% choosing between care and career, and 61% (74% for dual carers) facing direct impacts on their financial independence or vital career progression opportunities, often stalling their professional growth.

“Carers with supportive workplaces are significantly more likely to have healthy levels of wellbeing,” stresses Reid, highlighting benefits for employers.

The report underscores gender disparity: 48% of women feel societal pressure to be caregivers, and 64% believe they bear a greater family care burden.

Despite challenges, carers seek solutions like exercise (37%) and peer support (31%). Reid emphasises that strong support networks “make a genuine, tangible difference to their wellbeing and ability to cope with these immense pressures.”

For more information on the Sandwich Generation Report 2025, click here

Jane Hunter’s Exclusive Wine Dinner at The Ritz-Carlton, Bali

The First Lady of New Zealand Wine elevates the sumptuous creations of The Beach Grill.

Download images: https://marrstar.box.com/s/6dhnite6qk6fm3vnvmm6kcsrkhtdolpz 

BALI, Indonesia , June 4, 2025 /PRNewswire/ — The Ritz-Carlton, Bali is proud to present an unforgettable evening of culinary excellence and world-class wine at Jane Hunter’s Wine Dinner, hosted at The Beach Grill on Thursday, 5 June 2025.

Guests are invited to indulge in an exclusive multi-course dinner paired with award-winning wines from Hunter’s Wines, one of New Zealand’s most celebrated wineries. Led by Jane Hunter, the iconic vintner often referred to as the “First Lady of New Zealand Wine,” the evening will offer guests a rare opportunity to experience the story, passion, and craftsmanship behind each glass.

“This is more than just a wine dinner,” says Go Kondo, General Manager of The Ritz-Carlton, Bali. “It’s an immersive experience that blends fine dining, legendary hospitality from our Ladies and Gentlemen, and one of the most respected names in New World wine.”

Each course of the evening’s menu will be thoughtfully curated by the resort’s culinary team to complement the unique notes and characteristics of Jane Hunter’s premium vintages, including the renowned Sauvignon Blanc, Rosé, and Pinot Noir selections.

With limited seating available, this exclusive event promises a sophisticated evening of gourmet cuisine, expertly paired wines, and personal insights from Simon Mitchell – Jane Hunter’s Wine Representative.

The event will start at 6 p.m. at The Beach Grill on 5 June 2025. The price is at IDR 1,600,000 nett per person including four-course set menu and Jane Hunter’s wine pairing.

For reservation please visit our website https://www.thebeachgrillbali.com/

About The Ritz-Carlton, Bali

Built on a sprawling 12.7 hectares white beach front and elevated cliff top  settings, The  Ritz-Carlton, Bali feature 313 oceanfront suites and villas, enjoying the unobstructed view of the Indian Ocean and the resort’s lush garden. Completing the experiences, a glass elevator connects the cliff and the beach-front, five restaurants and bars, The Ritz-Carlton Ballroom and meeting facilities, a wedding chapel, as well as The Ritz-Carlton Spa. Ladies and gentlemen at The Ritz-Carlton, Bali is proudly presents the timeless charms of Indo-Balinese hospitality.

About The Ritz-Carlton Hotel Company, LLC

Delivering the Gold Standard in service in coveted destinations around the world, The Ritz-Carlton Hotel Company, LLC currently operates more than 120 hotels in over 35 countries and territories. From iconic urban destinations to stretches of paradise in untouched corners of the earth, The Ritz-Carlton offers the opportunity for true discovery and transformative escapes that stay with guests long after they depart. Committed to thoughtful innovation, The Ritz-Carlton encompasses two groundbreaking brand extensions, Ritz-Carlton Reserve and The Ritz-Carlton Yacht Collection. Ritz-Carlton Reserve is a collection of rare estates set apart from the world, where personalized care and cultural immersion are paramount. The Ritz-Carlton Yacht Collection translates the brand’s legendary service and hospitality for sea, reimagining the ultra-luxury cruising category. For more information or reservations, visit the company website at www.ritzcarlton.com, for the latest company updates, visit news.marriott.com and to join the live conversation, use #RCMemories and follow along on Facebook, Twitter, and Instagram. The Ritz-Carlton Hotel Company, L.L.C. is a wholly-owned subsidiary of Marriott International, Inc. (NASDAQ:MAR). The Ritz-Carlton is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including complimentary nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com. The Ritz-Carlton is committed to supporting the destinations where it operates through Community Footprints, the company’s social and environmental responsibility program.

J.S. Held Announces the First Global Consulting Company Chief Intellectual Property Officer

JERICHO, N.Y., June 4, 2025 /PRNewswire/ — Global consulting firm J.S. Held proudly announces the appointment of intellectual property (IP) expert James E. Malackowski as the first Chief Intellectual Property Officer (CIPO) of a global consulting company. J.S. Held Chief Executive Officer Lee Spirer observes, “In today’s knowledge-based economy, the role of CIPO serves an important strategic and operational role both internally and in support of clients.” 

Protecting J.S. Held Intellectual Property and Other Intangible Assets

J.S. Held experts have developed methodologies, frameworks, proprietary tools, and research that support client work. The CIPO partners across the business to ensure that these intangible assets are identified, protected, and leveraged to benefit the business. “Having dedicated IP leadership will help the company move faster in developing and deploying new methodologies, while ensuring reasonable measures of protecting our innovations,” noted James E. Malackowski.

Managing J.S. Held Intellectual Property and Other Intangible Assets

J.S. Held maintains a robust portfolio of patents including a “System and Method for Financing an Insurance Transaction”, trademarks, data, trade secrets, and other proprietary technologies that support client work. “As CIPO, I intend to partner with company leadership and our professional experts across the globe to manage and monetize the many patent, trademark, data, and other proprietary assets that set J.S. Held apart among our competitors, benefitting clients and our investors,” added James E. Malackowski. 

Industry’s Most Comprehensive Global Intellectual Property Consulting Group

Ocean Tomo, a part of J.S. Held, is rooted in an expansive understanding of intellectual property (IP) value and risk, providing a foundation of Expertise for the Innovation Economy™.  Built upon more than three decades of experience assessing IP in the most rigorous of venues – state, federal, and international courts, Ocean Tomo clients benefit from continuous feedback between litigation economic damage outcomes, transaction pricing, capital market valuations, debt financing terms, equity assessments, and deep technical insight.  The team possesses the most comprehensive and market-tested understanding of IP value. Financial, market, and technical experts uniquely understand the contributory value of patented inventions, know-how, brands, and copyrights that permeate every business, viewing IP not simply as an isolated asset, but as an integral component of enterprise value.

Multidimensional Intellectual Property-Informed Experts Benefit J.S. Held Clients

Intellectual property expertise permeates the global organization. Beyond the expertise within J.S. Held’s dedicated IP practice Ocean Tomo, a part of J.S. Held, multidisciplinary experts across J.S. Held combine intellectual property expertise to core specializations, including:

  • Artificial Intelligence (AI)
  • Business Intelligence
  • Construction Advisory
  • Enterprise Risk Management
  • Fraud Investigations
  • Forensic Accounting
  • Insurance Claims Consulting
  • Restructuring, Turnaround, Receivership, and Bankruptcy

J.S. Held Intangible Asset Market Value Study of MSCI World Mid-Cap Companies

Building upon the important Intangible Asset Market Value Study created by Ocean Tomo and accessed on more than 150,000 occasions, J.S. Held releases the study of the MSCI World Mid-Cap companies. As shown in the graph, intangible assets now command 72% of the MSCI World Mid-Cap market value. As of 2025, the intangible asset market value of the MSCI Mid-Cap World Index companies exceeds $8.3 trillion USD. 

Tangible and Intangible Asset Value Understanding

The depth and breadth of J.S. Held’s work in the property and casualty insurance market and Ocean Tomo’s work across all forms of intellectual property and other intangible assets uniquely combine to create a strong foundation in risk assessment, data analysis, global awareness, regulatory compliance, technological adaptability, and risk mitigation. Collectively, these skills better equip J.S. Held experts to assess business risk across diverse geographies, geopolitical landscapes, regulatory frameworks, and technological advancements for the benefit of our clients.  

Learn more about the new J.S. Held Chief Intellectual Property Officer, James E. Malackowski.

About J.S. Held

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

More than 1,500 professionals serve organizations across six continents, including 84% of the Global 200 Law Firms, 75% of the Forbes Top 20 Insurance Companies (90% of the NAIC top 50 Property & Casualty Insurers), and 71% of the Fortune 100 Companies.

Verdantix, in their Green Quadrant: Enterprise Risk Management Consulting Services (2025) report, benchmarks 15 of the most prominent enterprise risk management (ERM) advisors, identifying global consulting firm J.S. Held among the leading companies based on capabilities and momentum

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice.  Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC.  All rights reserved.

Find your expert.®

Contact
Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com

J.S. Held Intangible Asset Market Value Study of MSCI World Mid-Cap Companies
J.S. Held Intangible Asset Market Value Study of MSCI World Mid-Cap Companies

 

Video – https://www.youtube.com/watch?v=_Y2LBmohvJU 

 

WOGI Deepens Client and Merchant Ecosystem with UNIQGIFT Acquisition and New COO

By integrating UNIQGIFT and appointing Gregory Imbert as COO, WOGI enhances its operational strength to expand merchant partnerships and deepen client relationships.

SINGAPORE, June 4, 2025 /PRNewswire/ — WOGI, Asia’s trusted digital rewards and incentives solutions partner, today announced the acquisition of UNIQGIFT, Singapore’s leading provider of customised reward programs for customers, employees and partners. The deal, completed in late May, is part of WOGI’s strategy to scale strategic partnerships, extend client reach across Asia and grow its leadership capacity from its Singapore headquarters.

As part of the acquisition, UNIQGIFT CEO Gregory Imbert joins WOGI as Chief Operating Officer (COO) where he will lead the company’s partnerships and strategic alliances, oversee product development, and drive operational excellence across all markets. His appointment is a strategic move that reinforces WOGI’s commitment to strengthening enterprise support through direct, on-the-ground presence in key Asian markets—including Singapore, Malaysia, Hong Kong, Indonesia, Thailand, Vietnam, Japan, and Sri Lanka—while also accelerating its global reach and enhancing enterprise-grade service delivery.

“This strategic alignment reflects our commitment to intentional growth and client focus, enabling enterprises to manage personalised rewards and incentives at scale,” said Viktor Anastanov, CEO of WOGI. “It brings together two experienced players with deep knowledge of Asia’s cultural and operational complexity. Gregory brings a proven track record of client first execution and product innovation, further enhancing how we support clients across diverse markets.”

Reflecting on the integration and expanded reach, WOGI’s new COO, Gregory Imbert, noted: “Joining WOGI is an opportunity to extend what we built at UNIQGIFT into a broader platform which balances scale with a personal approach. Our clients gain access not only to a broader range of reward options across Asia, but also to WOGI’s powerful technology and enterprise-grade solutions that are designed to deliver seamless, scalable experiences.”

The integration unlocks new value for both UNIQGIFT clients and merchants partners. Clients previously limited to Singapore-only reward offerings now benefit from WOGI’s broader solution suite, regional service infrastructure, and merchant network spanning 47 markets. Merchant partners gain exposure to a wider client base, opening new opportunities to support campaigns and regional initiatives.

WOGI recently unveiled a new brand identity that reflects its mission to make rewards and incentives simple and meaningful across Asia and beyond. Since 2015, the company has served as a digital first platform built to address the complexities of Asia’s fragmented reward landscape. By unifying multiple currencies, thousands of brand partnerships, and robust compliance frameworks on a single platform, WOGI enables instant redemptions and seamless execution across the region.

Trusted by global organisations, WOGI powers millions of rewards and incentives that connect businesses with the people they serve across Asia and beyond. Its platform is built to serve the needs of diverse markets, combining local insight with global reach. It also offers enterprise level security and holds certification under ISO 9001:2015 and ISO/IEC 27001:2022. The company is backed by Blackhawk Network (BHN), a global leader in branded payments, which acquired a minority stake in 2022.

About WOGI

WOGI is an end-to-end digital rewards and incentives platform provider, designed to power rewards, performance, and loyalty across people and markets. WOGI enables organisations to deliver culturally relevant rewards and incentives that are simple to send and easy to manage. With local teams in eight Asian markets and coverage across 47 countries, WOGI brings together enterprises, brand partners, and payment networks to deliver impactful, culturally relevant rewards that reach people where it matters most.

Explore the platform at www.wogi.biz

About UNIQGIFT

Established in 2008, UNIQGIFT empowers organisations in Singapore to engage customers and employees in real time through innovative gifting, promotions, and loyalty solutions. UNIQGIFT is trusted by local government agencies, leading banks and insurance agencies. Its digital vouchers are accepted at top supermarkets, pharmacies, petrol stations, local cafes and more.

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the third oral presentation of clinical data for IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) in advanced non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO), following IBI363’s other two oral presentations in colorectal cancer and melanoma. A manageable safety profile, encouraging efficacy, and trends in long-term survival benefits have been observed in both immunotherapy-resistant squamous non-small cell lung cancer (NSCLC) and wild-type lung adenocarcinoma. It is worth mentioning that Innovent’s pipeline has a total of 8 oral presentations at this ASCO conference, representing approximately 2% of the conference’s total oral presentations.

Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 for multiple tumor indications, including immune resistance, cold tumors, and front-line treatments. At this year’s ASCO meeting, three oral presentations of IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—NSCLC, CRC, and melanoma—focusing on IO-resistant and cold tumors. The data comprehensively demonstrated the breakthrough clinical outcomes of IBI363 across these indications, from robust tumor response to long-term survival benefits. These findings provide strong support of the drug’s novel mechanism of action translating effectively into clinical outcomes, and imply its potential for broader clinical development, offering new hope in areas of immunotherapy where treatment options remain limited.

PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study

Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the data cutoff date, April 7, 2025, a total of 136 patients with NSCLC had received IBI363 monotherapy (2 μg/kg QW~4mg/kg Q3W), including 67 with squamous cell carcinoma and 58 with EGFR wild-type adenocarcinoma.

IBI363 showed breakthrough therapeutic potential from tumor response to long-term survival benefit in immuno-resistant squamous NSCLC

  • All 67 squamous NSCLC patients were EGFR wild type. Among them, 28 patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the two groups of patients, the proportion of ≥2 lines of previous systemic therapy was 64.3% (18/28) vs 67.7% (21/31), the proportion of previous anti-PD-1/PD-L1 therapy was 100% (28/28) vs 96.8% (30/31) and the proportion of PD-L1 TPS<1% was 35.7% (10/28) vs 41.9% (13/31).
  • In the 1/1.5 mg/kg dose group, promising ORR/DCR/PFS/OS were observed. Median OS achieved 15.3 months, suggesting the potential long-term survival benefit of IBI363 as a PD-1/IL-2α-bias bispecific immunotherapy.
  • Compared with the 1/1.5 mg/kg dose group, the 3 mg/kg Q3W dose group observed more prominent confirmed ORR (36.7%), DCR (90.0%), PFS (median PFS 9.3 months) and OS trends (median OS not reached, 12-month OS rate 70.9%) (see the table below).

Squamous NSCLC

1/1.5 mg/kg

(n=28)

3 mg/kg

(n=31)

Confirmed ORR, % (95% CI)*

25.9 (11.1, 46.3)

36.7 (19.9, 56.1)

DCR, % (95% CI)*

66.7 (46.0, 83.5)

90.0 (73.5, 97.9)

Median PFS, month (95% CI)

5.5 (1.5, 8.3)

9.3 (6.2, 11.7)

Median PFS follow up time, month (95% CI)

16.5 (14.1, 19.5)

11.3 (10.1, 14.0)

Median OS, month (95% CI)

15.3 (7.6, NC)

NC (10.4, NC)

12-month OS rate, % (95% CI)

58.2 (37.3, 74.3)

70.9 (49.5, 84.5)

Median OS follow up time, month (95% CI)

17.3 (15.3, 20.2)

11.3 (10.3, 11.6)

*Note: One patient in each cohort finished treatment without at least one post-baseline tumor assessment.

  • Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg/kg group (N=13) were 46.2% and 92.3%, suggesting the potential advantage of IBI363 in the population with low expression of PD-L1.

IBI363 showed potential for long-term survival benefits in immuno-resistant wild-type lung adenocarcinoma, especially in patients with smoking history

  • Among the 58 patients with EGFR wild-type lung adenocarcinoma, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, 25 patients received IBI363 at 3 mg/kg Q3W. In the two groups of patients, the proportions of ≥2 lines of previous systemic therapy were 80.0% (24/30) vs 64.0% (16/25), the proportions of previous anti-PD-1/PD-L1 therapy were both 100%, the proportions of PD-L1 TPS<1% were 26.7% (8/30) vs 40.0% (10/25) and the proportions of smoking history were 56.7% (17/30) vs 60.0% (15/25).
  • In the 1/1.5 mg/kg dose group, median OS achieved 17.5 months, suggesting the potential long-term survival benefit of IBI363 as a PD-1/IL-2α-bias bispecific immunotherapy.
  • Compared with the 0.6/1/1.5 mg/kg dose group, the 3 mg/kg dose group observed higher confirmed ORR (24.0%), DCR (76.0%), PFS (median PFS 5.6 months) and OS trends (median OS not reached, 12-month OS rate 71.6%) (see the table below).

EGFR wild type adenocarcinoma

0.6/1/1.5 mg/kg

(n=30)

3 mg/kg

(n=25)

Confirmed ORR, % (95% CI)*

13.8 (3.9, 31.7)

24.0 (9.4, 45.1)

DCR, % (95% CI)*

62.1 (42.3, 79.3)

76.0 (54.9, 90.6)

Median PFS, month (95% CI)

2.7 (1.4, 5.1)

5.6 (3.1, 9.4)

Median PFS follow up time, month (95% CI)

21.9 (3.1, 21.9)

10.1 (6.1, 11.2)

Median OS, month (95% CI)

17.5 (5.6, NC)

NC (9.4, NC)

12-month OS rate, % (95% CI)

58.2 (38.3, 73.8)

71.6 (45.9, 86.6)

Median OS follow up time, month (95% CI)

17.7 (17.1, 20.9)

10.2 (9.1, 11.4)

* Note: one patient in 0.6/1/1.5mg/kg group finished treatment without at least one post-baseline tumor assessment.

  • Higher ORR and PFS were observed in lung adenocarcinoma patients with a history of smoking. Among them, the confirmed ORR in the 0.6/1/1.5 mg/kg group (N=17) was 23.5%, and the confirmed ORR in the 3 mg/kg group (N=15) was 33.3%. In all dose groups (N=32), the median PFS of smokers was longer than non-smokers: 5.3 (2.0, 7.0) vs 3.0 (1.6, 5.1) months. In terms of long-term survival benefits, after follow-ups of 12.0 and 13.7 months, the median OS for non-smokers was 13.6 months, whereas the median OS for smokers was not yet reached, with only 9 (28.1%) events occurring.

IBI363 had a manageable safety profile in advanced NSCLC

  • Among the 57 patients with NSCLC in the 3 mg/kg dose group, the most common treatment related adverse events (TRAEs) of grade 3 or above were arthralgia and rash. 7.0% of patients experienced TRAEs leading to discontinuation. The overall safety profile was manageable.

In view of the encouraging efficacy signals and manageable safety demonstrated by IBI363 monotherapy, Innovent plans to conduct a Phase 3 registration clinical study in locally advanced or metastatic squamous NSCLC that has failed platinum-based chemotherapy and anti-PD-1 /PD-L1 immunotherapy. As of now, IBI363 has received Breakthrough Therapy (BTD) certification from China CDE and Fast Track Designation (FTD) from the US FDA for squamous NSCLC.

Professor Jianya Zhou, The First Affiliated Hospital, School of Medicine, Zhejiang University, stated: “Lung cancer is the malignant tumor with the highest incidence and mortality rate both globally and in China[1], and it is a major issue endangering public health. Although immunotherapy has completely transformed the treatment landscape of NSCLC, for patients with wild-type NSCLC who have failed immunotherapy, the current standard treatment regimen docetaxel has limited efficacy, with an ORR of less than 20%, a PFS of less than 4 months, and an OS of less than 12 months [2-7]. In recent years, although the exploration of new treatment regimens such as immune combination therapy and antibody drug conjugates (ADCs) has brought new hope, many large-scale Phase 3 clinical studies on NSCLC patients who have failed platinum-based chemotherapy and immunotherapy have not achieved satisfactory results, and most of these studies have not met the primary endpoints[2-6]. Although the TROPION-Lung01 study achieved the primary endpoint of PFS in NSCLC, it did not reach the primary endpoint of OS. Especially in squamous NSCLC, no improvement was observed in PFS/OS/ORR in the experimental group. Therefore, there was a huge and urgent unmet medical need in NSCLC that has failed immunotherapy. As a PD-1/IL-2α-bias bispecific molecule, IBI363 not only shows clinical benefits in both ORR and PFS in immune-resistant NSCLC, but also enables us to see the potential of the tailing effect of immunotherapy to bring long-term survival benefits to patients compared with chemotherapy. We are also more looking forward to the survival data of the long-term follow up in the high dose IBI363 group.”

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “It is a great pleasure to orally present the latest progress of IBI363 in the field of lung cancer at the ASCO conference. IBI363 shows remarkable efficacy in immune-resistant wild-type nsclc and clinical data suggests better trends in ORR, DCR, PFS and OS at higher doses. We expect longer-term follow-up to bring more mature data and look forward to seeing its potential as an immunotherapy for the long-term survival benefits of patients. Meanwhile, regardless of the expression level of PD-L1, IBI363 has demonstrated a powerful anti-tumor effect in immune-resistant NSCLC (especially squamous NSCLC), suggesting that the effect of IBI363 does not depend on the expression of PD-L1. In the future, it may also bring breakthroughs in cold tumors with low or no expression of PD-L1. We will continue to advance the clinical exploration of IBI363 in NSCLC and other tumor types.”

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This approach targets and activates tumor-specific T cells that express both PD-1 and IL-2α, leading to more precise and effective activation of this T cell subpopulation. IBI363 has demonstrated robust antitumor activity in various tumor-bearing pharmacological models, but also showed outstanding efficacy in PD-1 resistance and metastasis models. 

In response to urgent clinical needs, Innovent is conducting clinical studies in China, the United States and Australia to further explore the efficacy and safety of IBI363 in various tumor indications, including immune-resistant, cold tumors, and front-line treatments. The first pivotal trial of IBI363 was initiated in 2025 for unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy.

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the China NMPA, for the treatment of squamous non-small cell lung cancer and melanoma, respectively.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com , or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

[1] Globocan 2022 (version 1.1) – 08.02.2024

[2] Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. Aug 20 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733

[3] Neal J, Pavlakis N, Kim SW, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. Jul 10 2024;42(20):2393-2403. doi:10.1200/JCO.23.02166

[4] SAFFRON-301: Tislelizumab plus sitravatinib in advanced/metastatic NSCLC progressing on/after chemotherapy and anti–PD-(L)1. WCLC 2024.

[5] 65O – Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. ESMO IO 2023.

[6] Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer . 2024 Mar:189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16.

[7] Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. Sep 9 2024:JCO2401544. doi:10.1200/JCO-24-01544

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

News Summary

  • Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1
  • Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2
  • Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications.

BALTIMORE and MILFORD, Mass., June 4, 2025 /PRNewswire/ — 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency.

Waters announced the launch of the Xevo TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole.
Waters announced the launch of the Xevo TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole.

“Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape,” said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. “The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers.”

Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance.

Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing.

“Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed,” said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. “We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities.”

In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers.

The Xevo TQ Absolute XR Mass Spectrometer is available to order now.

Additional Resources

Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation.

ABOUT:

Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

Contact:

Molly Gluck
Head of External Communications
Waters Corporation
molly_gluck@waters.com
Mobile: +1.617.833.8166

  1. Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed.
  2. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic]